Main Research Findings

1) Treatment with sunifiram was shown to reduce memory-related deficits and impaired long term potentiation induced by OBX, in the hippocampal CA1 region.

2) Administration of sunifiram has been shown to enhance hippocampal synaptic efficacy through glycine-binding sites of N-Methyl-D-Aspartate receptors.

 

Selected Data

1) The research team of Moriguchi et al investigated the effects of sunifiram, alone or in combination with gavestinel, on behavior and neurophysiological parameters in mice that had undergone olfactory bulbectomy (OBX), a procedure often used as an animal model for depression and cognitive impairment. The study used adult male DDY mice, aged 8–9 weeks. The mice were housed in standard laboratory conditions with constant temperature and humidity, under a controlled 12-hour light/dark cycle. They had free access to food and water.

Olfactory bulbectomy was performed on the mice as previously described in cited literature. Following surgery, the mice were given a recovery period before drug administration began. Treatments with sunifiram alone or in combination with gavestinel started 10 days after the OBX procedure and continued once daily for a period of 7 to 12 days. Behavioral testing occurred after 7–8 days of drug treatment, while electrophysiological and biochemical experiments were conducted after 9–12 days of treatment [1].

Notably, the researchers excluded any mice that exhibited aggressive behavior post-surgery, although none showed stereotypical killing behavior within three weeks after olfactory bulbectomy. To maintain consistency in the study, 3 or 4 mice were housed per cage and received the same drug treatment. At the conclusion of the experiments, all animals were sacrificed, and the OBX lesions were confirmed through histological analysis [1].

Sunifiram was dissolved in carboxymethylcellulose and administered orally via a gastric tube. Two different dosages were used of either 0.1 mg/kg and 1.0 mg/kg, administered in a volume of 1 ml per 100 g of body weight. The control group received only the vehicle solution of carboxymethylcellulose. Gavestinel was dissolved in tap water and administered intraperitoneally at a dose of 10 mg/kg. A separate control group for gavestinel received injections of plain tap water.

Several behavioral paradigms were used to assess cognitive and affective outcomes of the treatments. The first outcome measure was the Y-maze task, which evaluated spontaneous alternation behavior as a measure of spatial reference memory. The Y-maze consisted of three equal arms made of black Plexiglas. Each mouse was placed at the end of one arm and allowed to explore freely for 8 minutes. Alternation behavior was defined as entering all three arms consecutively. The percentage of alternation was calculated relative to the maximum number of possible alternations. The total number of arm entries was also recorded to account for general activity levels [1].

Another behavioral assessment was the novel object recognition task, designed to test recognition memory. Mice were habituated to an open field box for two days before testing. During the acquisition phase, two identical objects were placed in the center of the chamber. After an hour, one object was replaced with a novel one, and the mice’s exploratory behavior was observed for another 5 minutes. Exploration was defined by close inspection or physical interaction with the object. Preference for the novel object indicated successful recognition memory. Care was taken to clean the objects with ethanol between trials to avoid olfactory cues. The measure of interest was the proportion of time spent exploring the novel versus familiar objects [1].

Finally, the tail suspension task was employed to assess depression-like behavior. In this test, mice were suspended by their tails using adhesive tape for 10 minutes in a visually and acoustically isolated environment. The duration of immobility, defined as the period the animal remained completely motionless, was recorded. Reduced immobility time is generally interpreted as an antidepressant-like effect.

To explore changes at the synaptic level, hippocampal slices were prepared using a vibratome to obtain 400 µm-thick transverse sections. These slices were incubated in oxygenated artificial cerebrospinal fluid for 2 hours at room temperature. After recovery, the slices were placed in an interface chamber and perfused with warmed artificial cerebrospinal fluid at a constant rate. Field excitatory postsynaptic potentials were elicited by stimulating the Schaffer collateral/commissural pathway and recorded from the CA1 region using a glass microelectrode. Long-term potentiation was induced by high-frequency stimulation, consisting of two 1-second bursts at 100 Hz with a 10-second interval. Following electrophysiological recordings, the CA1 regions were isolated and stored at –80°C for subsequent biochemical analysis [1].

2) The experiment performed by researchers Moriguchi et al investigated the neuropharmacological effects of sunifiram, a nootropic compound, in mice. The researchers used adult male C57BL/6N mice, aged 8 to 9 weeks.. These animals were housed under standardized environmental conditions, including a constant temperature and relative humidity, with a 12-hour light/dark cycle. The mice had unrestricted access to food and water [2].

Electrophysiological studies were a key component of the research. Transverse slices of the hippocampus, each 400 micrometers thick, were cut using a vibratome and were incubated in artificial cerebrospinal fluid that was continuously oxygenated with a gas mixture of 95% oxygen and 5% carbon dioxide at room temperature for a period of two hours. After this recovery phase, the slices were transferred to an interface-type recording chamber where they were perfused at a steady rate of 2 ml per minute with artificial cerebrospinal fluid maintained at 34°C.

Field excitatory postsynaptic potentials were elicited by a low-frequency test stimulus of 0.05 Hz delivered through a bipolar electrode positioned on the Schaffer collateral/commissural pathway. These field excitatory postsynaptic potentials were recorded from the stratum radiatum of the hippocampal CA1 region using a glass microelectrode filled with a 3 M NaCl solution. To induce long-term potentiation, a high-frequency stimulation protocol consisting of two trains of 100 Hz stimuli, each lasting one second and spaced 10 seconds apart, was applied. After the electrophysiological recordings were completed, the hippocampal slices were quickly cooled on ice to enable precise dissection of the CA1 region, which was then flash-frozen in liquid nitrogen and stored at -80°C until it could be subjected to biochemical analysis [2].

Various primary antibodies were employed to examine the phosphorylation status and protein expression levels of key signaling molecules in the hippocampal CA1 region. These included antibodies specific for phosphorylated and total CaMKII, as well as those for phosphorylated PKCα at Ser-657, total PKCα, diphosphorylated ERK1/2 , total ERK, phosphorylated GluR1 at Ser-831, total GluR1, and phosphorylated synapsin I at Ser-603. Additional antibodies targeted phosphorylated NR1 at Ser-896, total NR1, phosphorylated Src family kinases at Tyr-416, and β-tubulin, the latter serving as a loading control. Detection of bound antibodies was carried out using the enhanced chemiluminescence method, a widely used technique for visualizing proteins on Western blots. Signal intensities were quantified semi-quantitatively using image analysis software [2].

In addition to the biological materials, the study utilized several pharmacological agents to manipulate the activity of specific receptors and signaling pathways. These included DL-2-amino-5-phosphonovaleric acid, a well-known NMDA receptor antagonist; 7-chlorokynurenic acid, which inhibits the glycine-binding site of NMDA receptors; and ifenprodil, which blocks the polyamine-binding site of NMDA receptors. Other compounds included PP2, a Src family kinase inhibitor; a metabotropic glutamate receptor agonist; and glycine.

Overall, this section of the study outlines a comprehensive and methodological approach to evaluating the molecular and electrophysiological effects of sunifiram on hippocampal function in a mouse model. Through the integration of electrophysiological recordings, Western blotting, and pharmacological interventions, the researchers were able to dissect the pathways modulated by sunifiram, including those involving NMDA receptor subunits, protein kinases like CaMKII and PKC, and downstream effectors such as GluR1. These techniques allowed for a detailed investigation of how sunifiram might enhance synaptic plasticity and potentially ameliorate cognitive deficits in animal models of neurological disorders [2].

 

Discussion

1) The study completed by Moriguchi et al investigated the effects of sunifiram, a cognitive-enhancing compound, on memory, depression-like behaviors, synaptic plasticity, and associated molecular mechanisms in olfactory bulbectomized (OBX) mice in a model used to mimic certain features of cognitive and mood disorders. The results were structured into five primary findings, each exploring specific behavioral and biochemical outcomes following sunifiram administration, with or without co-treatment using gavestinel, a glycine-site antagonist of NMDA receptors [1].

Initially, the researchers evaluated the impact of sunifiram on spatial memory using the Y-maze task. OBX mice exhibited impaired memory performance, demonstrated by a reduced percentage of spontaneous alternations compared to sham-operated control mice, while total arm entries remained unaffected. Treatment with sunifiram at a dose of 1.0 mg/kg significantly restored memory performance to levels comparable to the control group, suggesting that sunifiram effectively improved cognitive deficits induced by OBX. However, this improvement was blocked by gavestinel, indicating that sunifiram’s effect on memory may be mediated via the glycine-binding site of NMDA receptors [1].

In the novel object recognition test, a task assessing recognition memory based on the natural tendency of rodents to explore novel stimuli, OBX mice were unable to distinguish between familiar and novel objects. In contrast, sunifiram-treated OBX mice displayed a significant preference for the novel object, further supporting the compound’s pro-cognitive effects. Similar to the Y-maze results, gavestinel inhibited this improvement, again implicating NMDA receptor activation in sunifiram’s efficacy.

The study then explored the effect of sunifiram on depression-like behavior using the tail suspension test, a well-established measure to assess antidepressant activity. OBX mice showed increased immobility time, indicative of depression-like behavior. However, sunifiram administration at doses ranging from 0.01 to 1.0 mg/kg did not reduce immobility time, suggesting that while the drug enhances memory-related functions, it does not ameliorate depression-like symptoms in OBX mice [1].

The researchers next examined whether sunifiram affects long-term potentiation, a synaptic mechanism underlying learning and memory, in hippocampal slices from OBX mice. In sham-operated mice, high-frequency stimulation induced robust long-term potentiation in the CA1 region, while OBX mice displayed significantly attenuated long-term potentiation. Treatment with sunifiram significantly restored long-term potentiation in OBX mice, especially at the 1.0 mg/kg dose, suggesting that sunifiram effectively reverses OBX-induced deficits in synaptic plasticity. Importantly, gavestinel pretreatment prevented this recovery, reinforcing the notion that sunifiram enhances long-term potentiation via activation of the glycine-binding site of NMDA receptors [1].

To investigate the molecular underpinnings of sunifiram’s effects, the study assessed key proteins involved in synaptic function and plasticity. OBX significantly reduced the autophosphorylation of CaMKIIα at Thr-286 and the phosphorylation of GluR1 at Ser-831 in the hippocampal CA1 region. Both modifications are critical for long-term potentiation induction and maintenance. Sunifiram treatment dose-dependently restored the phosphorylation levels of these proteins, reaching near or slightly above control levels at 1.0 mg/kg. Again, gavestinel blocked these effects, indicating that sunifiram acts through NMDA receptor-dependent pathways to regulate these signaling molecules.

Further molecular analysis revealed that OBX also impaired the autophosphorylation of PKCα at Ser-657 and the phosphorylation of the NMDA receptor NR1 subunit at Ser-896: two processes associated with NMDA receptor function and memory. Sunifiram significantly enhanced both PKCα and NR1 phosphorylation in a dose-dependent manner, with the most pronounced effects observed at 1.0 mg/kg. This recovery was also abolished by gavestinel pretreatment, again implicating NMDA receptor glycine-site activation in the mechanism of action of sunifiram [1].

Despite its effects on several kinases and receptor subunits, sunifiram did not influence all signaling pathways affected by OBX. The study specifically examined CaMKIV and ERK, both of which are implicated in synaptic plasticity and memory consolidation. OBX markedly reduced phosphorylation of both CaMKIV and ERK in the hippocampal CA1 region. However, sunifiram treatment at any of the tested doses did not restore phosphorylation levels of these proteins, suggesting that sunifiram’s cognitive-enhancing effects may bypass these particular signaling cascades or require additional co-factors or stimuli not present under the experimental conditions [1].

In summary, this study demonstrated that sunifiram effectively reverses OBX-induced memory impairments in mice, as shown by behavioral tasks and electrophysiological recordings of long-term potentiation. The improvements were closely associated with restored phosphorylation of key proteins involved in synaptic plasticity, particularly those linked to NMDA receptor signaling, such as CaMKII, GluR1, PKCα, and NR1. Importantly, these beneficial effects were abolished by gavestinel, indicating a strong dependence on the glycine-binding site of NMDA receptors. However, sunifiram did not impact depressive behaviors or restore phosphorylation of CaMKIV and ERK, pointing to a degree of pathway specificity in its mechanism of action. These findings suggest that sunifiram may hold promise as a cognitive enhancer, particularly for disorders characterized by NMDA receptor dysfunction, although its lack of antidepressant effects limits its therapeutic scope [1].

2) The investigation performed by the research team of Moriguchi et al assesses the effects of sunifiram on synaptic plasticity, specifically long-term potentiation, in the hippocampal CA1 region of mouse brain slices. Long-term potentiation is a sustained enhancement in synaptic strength following high-frequency stimulation, and it serves as a widely accepted model for studying the cellular mechanisms underlying learning and memory. The researchers sought to determine how sunifiram influences long-term potentiation and to elucidate the molecular mechanisms involved, focusing particularly on the N-methyl-D-aspartate receptor (NMDAR) and related intracellular signaling pathways [2].

Initial experiments demonstrated that sunifiram significantly enhanced long-term potentiation in the hippocampal CA1 region at a concentration of 10 nM, with potentiation levels reaching approximately 256.6% of control values 60 minutes after high-frequency stimulation. This enhancement was not observed at either lower concentrations of 1 nM or higher concentrations of 1,000 nM, suggesting a narrow effective concentration range. The enhancement of long-term potentiation by sunifiram was abolished by 7-chloro-kynurenic acid, an inhibitor of the glycine-binding site on the NMDAR, but not by ifenprodil, an inhibitor of the polyamine-binding site. This indicates that sunifiram acts specifically through the glycine-binding site of NMDAR to exert its effects.

Further investigation into the molecular mechanisms underlying sunifiram’s effects revealed increased autophosphorylation of Ca2+/calmodulin-dependent protein kinase II alpha (CaMKIIα) at Thr-286 and increased phosphorylation of the GluR1 AMPA receptor subunit at Ser-831 after long-term potentiation induction in the presence of sunifiram. These changes were dependent on glycine-binding site activation, as they were significantly attenuated by 7-chloro-kynurenic acid but not by ifenprodil. Interestingly, phosphorylation of synapsin I, a presynaptic marker, remained unchanged, suggesting that sunifiram’s effects are specific to postsynaptic signaling pathways [2].

Protein kinase C alpha (PKCα), another key kinase in synaptic plasticity, was also activated by sunifiram, as evidenced by increased autophosphorylation at Ser-657. In parallel, phosphorylation of the NR1 subunit of the NMDAR at Ser-896, a known PKC target, was also elevated. Both events were further enhanced during long-term potentiation induction in the presence of sunifiram. As with CaMKIIα, these effects were significantly inhibited by 7-chloro-kynurenic acid but not by ifenprodil, reinforcing the role of the glycine-binding site in mediating sunifiram’s activity [2].

Despite the extensive changes in CaMKII and PKC signaling, extracellular signal-regulated kinase (ERK) phosphorylation remained unchanged with sunifiram treatment, suggesting that ERK is not involved in the compound’s enhancement of long-term potentiation. In contrast, sunifiram stimulated phosphorylation of Src family kinases at Tyr-416 and the NR2B subunit of the NMDAR at Tyr-1472 in a dose-dependent manner, with maximum effects at 10 nM. These signaling changes were also inhibited by 7-chloro-kynurenic acid and by PP2, a selective Src family kinase inhibitor, but not by ifenprodil.

Functional measurements of field excitatory postsynaptic potentials confirmed that sunifiram enhanced synaptic responses in a dose-dependent fashion. A minimum effective concentration of 100 nM increased field excitatory postsynaptic potential slope by approximately 120.5% of control, while the maximum effect was seen at 1 µM. These physiological enhancements correspond with the molecular changes induced by sunifiram [2].

To directly test the role of PKC and Src family kinases in sunifiram-mediated long-term potentiation enhancement, the authors employed pharmacological inhibitors. Treatment with DL-2-amino-5-phosphonovaleric acid (APV), a general NMDAR antagonist, 7-chloro-kynurenic acid, or PP2 effectively blocked the phosphorylation of PKCα and Src family kinases induced by sunifiram. In contrast, ifenprodil had no such effect. These findings strengthen the conclusion that sunifiram’s enhancement of long term potentiation is dependent on NMDAR activation through the glycine-binding site and downstream activation of PKC and Src kinases [2].

Lastly, the study tested whether sunifiram’s effects could be further enhanced by saturating the glycine-binding site with exogenous glycine. When 300 µM glycine was added to the artificial cerebrospinal fluid sunifiram failed to further potentiate long-term potentiation, suggesting that its action is dependent on modulating the availability or efficacy of glycine binding to the NMDAR. This finding reinforces the conclusion that sunifiram’s mechanism is tightly linked to its interaction with the glycine-binding site.

In conclusion, this study demonstrates that sunifiram enhances hippocampal long-term potentiation via activation of the glycine-binding site of NMDARs. This action leads to downstream activation of CaMKIIα, PKCα, and Src family kinases, resulting in increased phosphorylation of key synaptic proteins such as GluR1 and NR1. The effects of sunifiram display a bell-shaped dose-response curve and are abolished by inhibitors of the glycine-binding site, NMDARs in general, and Src kinases, but not by inhibitors targeting other sites. These findings suggest that sunifiram modulates synaptic plasticity through a specific and tightly regulated molecular pathway, highlighting its potential as a cognitive enhancer and a valuable tool for investigating NMDAR-dependent signaling mechanisms [2].

 

Disclaimer

**LAB USE ONLY**
*This information is for educational purposes only and does not constitute medical advice. THE PRODUCTS DESCRIBED HEREIN ARE FOR RESEARCH USE ONLY. All clinical research must be conducted with oversight from the appropriate Institutional Review Board (IRB). All preclinical research must be conducted with oversight from the appropriate Institutional Animal Care and Use Committee (IACUC) following the guidelines of the Animal Welfare Act (AWA).

 

Citations

[1] Moriguchi S, Tanaka T, Tagashira H, Narahashi T, Fukunaga K. Novel nootropic drug sunifiram improves cognitive deficits via CaM kinase II and protein kinase C activation in olfactory bulbectomized mice. Behav Brain Res. 2013;242:150-157. doi:10.1016/j.bbr.2012.12.054

[2] Moriguchi S, Tanaka T, Narahashi T, Fukunaga K. Novel nootropic drug sunifiram enhances hippocampal synaptic efficacy via glycine-binding site of N-methyl-D-aspartate receptor. Hippocampus. 2013;23(10):942-951. doi:10.1002/hipo.22150

 

Sunifiram is sold for laboratory research use only. Terms of sale apply. Not for human consumption, nor medical, veterinary, or household uses. Please familiarize yourself with our Terms & Conditions prior to ordering.